Market closed

Cencora/$COR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Cencora

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Ticker

$COR
Sector
Health Care

Trading on

NYSE

Industry

Health Care Providers & Services
Headquarters
Conshohocken, United States

Employees

44,000
Website
www.cencora.com

Cencora Metrics

BasicAdvanced
$46B
31.35
$7.53
0.46
$2.08
0.93%

$46B

0.46

$249.83

$214.77

1.2M

$2.08

0.879

0.498

484.497

557.753

27.58%

20.45%

2.93%

209.12%

31.353

0.159

58.9

-3.7

15.634

0.88%

0.93%

12.12%

-11.72%

11.16%

0.63%

5.04%

What the Analysts think about Cencora

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cencora stock.

Cencora Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cencora Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Cencora News

AllArticlesVideos
Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth

Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth

Seeking Alpha·2 days ago
Cencora raises annual profit forecast

Cencora raises annual profit forecast

Reuters·2 weeks ago
Cencora Completes Acquisition of Retina Consultants of America

Cencora Completes Acquisition of Retina Consultants of America

Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COR

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cencora stock?

Cencora (COR) has a market cap of $46B as of January 15, 2025.

What is the P/E ratio for Cencora stock?

The price to earnings (P/E) ratio for Cencora (COR) stock is 31.35 as of January 15, 2025.

Does Cencora stock pay dividends?

Yes, the Cencora (COR) stock pays dividends to shareholders. As of January 15, 2025, the dividend rate is $2.08 and the yield is 0.93%. Cencora has a payout ratio of 27.58% on a trailing twelve-month basis.

When is the next Cencora dividend payment date?

The next Cencora (COR) dividend payment date is unconfirmed.

What is the beta indicator for Cencora?

Cencora (COR) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.